Popular terms

Cytokine topics
Antibodies
Inflammation
Specificity
Immunotherapy
Major Histocompatibility Complex
Compatibility
Combination Therapy
Histocompatibility
Immune Response
Monoclonal Antibody
Stimulator
Therapeutics
Immunostimulator
Monoclonal
Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cytokine patents



      

This page is updated frequently with new Cytokine-related patent applications.




Date/App# patent app List of recent Cytokine-related patents
07/21/16
20160209426 
 Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists patent thumbnailnew patent Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
Methods of assessing or monitoring the effect, efficacy, responsiveness to treatment, and/or determining a dose or dosing regimen of therapeutic agents, such as integrin beta7 antagonists, for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of using integrin beta7 subunit-containing receptor occupancy by the integrin beta7 antagonist on colonic lymphocytes as an indicator (“biomarker”) of the effect, efficacy, or responsiveness to treatment, and/or as a means to determine dosing or dosing regimens of therapeutic agents such as beta7 integrin antagonists for the treatment of gastrointestinal inflammatory disorders are provided.
Genentech, Inc.


07/21/16
20160206700 
 Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue patent thumbnailnew patent Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hghrelin.. .
Ipsen Pharma S.a.s.


07/21/16
20160206681 
 Method for treating cognitive dysfunction patent thumbnailnew patent Method for treating cognitive dysfunction
The present invention provides compositions and methods for treating cognitive impairment or dysfunction in a subject. In particular, the present invention provides a method for using a composition comprising an angiotensin-(1-7) receptor agonist to treat cognitive dysfunction or impairment that is due to a various clinical conditions including, but not limited to, those associated with increase in inflammation, cytokine production, increases in reactive oxygen species, changes in expression of brain inflammatory related genes and/or in the expression of genes involved in learning and memory within the central nervous system of a subject..
Arizona Board Of Regents For The University Of Arizona


07/14/16
20160200815 
 Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof patent thumbnailAntibodies that inhibit tim-3:lilrb2 interactions and uses thereof
Provided herein are embodiments relating to therapeutic applications of antibodies that modulate; e.g., inhibit the interaction of tim-3 and lilrb2 antibodies. In some embodiments, the antibodies bind tim-3.
Jounce Therapeutics, Inc.


07/14/16
20160199450 
 Scaffolds containing cytokines for tissue engineering patent thumbnailScaffolds containing cytokines for tissue engineering
The present disclosure provides biocompatible scaffold that promotes m1 or m2 macrophage phenotypes so as to increase vascularization or healing. Also provided are methods of treating a subject in need with the scaffolds described here..
The Trustees Of Columbia University In The City Of New York


07/14/16
20160199339 
 Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma patent thumbnailComposition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma
The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of il-4 in el-4 cells, which are mouse t cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube.
Korea Research Institute Of Bio Science And Biotechnology


07/07/16
20160194322 
 Substituted imidazo ring systems and methods patent thumbnailSubstituted imidazo ring systems and methods
Imidazo ring systems substituted at the 1-position, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.. .
3m Innovative Properties Company


07/07/16
20160193314 
 Partial peptide of survivin presented on mhc class ii molecule and use thereof patent thumbnailPartial peptide of survivin presented on mhc class ii molecule and use thereof
The object aims to provide: a novel tumor antigen; a novel therapeutic agent useful in a method for treating a malignant neoplasm by utilizing the tumor antigen; and a tumor antigen which can be used as the therapeutic agent. Thus, disclosed are: a novel tumor antigen which has an epitope capable of inducing a th1 cell which is a cd4-positive t cell specific to survivin; and use of the tumor antigen.
Tella, Inc.


07/07/16
20160193313 
 Immunogenic compositions and methods for treating neoplasia patent thumbnailImmunogenic compositions and methods for treating neoplasia
The invention provides immunogenic compositions comprising neoplastic cells expressing a cytokine (gm-csf) formulated with at least one tlr agonist and methods of using the composition to induce or enhance an immune response.. .
The Johns Hopkins University


07/07/16
20160193292 
 Cell permeable inhibitors of the scaffold protein plenty of sh3 domains (posh) or sh3rfl patent thumbnailCell permeable inhibitors of the scaffold protein plenty of sh3 domains (posh) or sh3rfl
Plenty of sii3 (posh) and ink-interacting protein 1 (jip-1) function as a multi-protein scaffold network for tcr-mediated jnk1 activation in cd8+ t-cells. Disruption of the posh/jip-1 complex led to profound defects in the activation of jnk1, as well as deficient activation or induction of the transcription factors c-jun, t-bet and eomesodermin furthermore, disruption of the posh/jip complex in cd8+t-cells resulted in impaired proliferation, decreased cytokine expression and the inability to control tumors.
The Curators Of The University Of Missouri


07/07/16
20160193249 

Treatment of inflammatory diseases by carbon materials


In some embodiments, the present disclosure pertains to methods of treating an inflammatory disease in a subject by administering a carbon material to the subject. In some embodiments, the carbon material selectively targets t cells in the subject.
Baylor College Of Medicine


07/07/16
20160193180 

Composition for preventing and treating immune diseases containing daurinol compound as active ingredient


The daurinol compound according to the present invention exhibits excellent therapeutic effects on arthritis and inflammatory bowel diseases by having an excellent activity in inhibiting the generation of il-17 and tnf-α, which are inflammatory cytokines causing inflammation, and can alleviate transplant rejection by inhibiting the proliferation of alloreactive t cells and increasing regulatory t cells; therefore, the daurinol compound according to the present invention can be used as a pharmaceutical composition capable of treating and preventing immune diseases. In addition, being a natural substance derived from the mongolian medicinal plant haplophyllum dauricum or haplophyllum cappadocicum, the daurinol compound according to the present invention does not cause cytotoxicity and thus may be used as a composition for a functional health food capable of preventing and remedying immune diseases..
The Catholic University Of Korea Industry-academic Cooperation Foundation


07/07/16
20160192985 

Methods for therapeutic renal neuromodulation


Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.


07/07/16
20160192984 

Methods for bilateral renal neuromodulation


Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.
Medtronic Ardian Luxembourg S.a.r.l.


07/07/16
20160192627 

Humanized mice expressing the pyrin domain only protein 2


A transgenic mouse expressing the human gene for pyrin domain-only protein 2 (pop2). Pop2, when expressed in the transgenic mouse model, broadly dampens inflammatory cytokine production, in part through restricting the activation of both nlrp3 and aim2 inflammasomes.
Albany Medical College


06/30/16
20160185847 

Use of monoclonal antibodies for the treatment of inflammation and bacterial infections


A composition includes monoclonal antibodies directed against a circulating proinflammatory cytokine, the antibodies having a high affinity for the fcγriiia receptor (cd16), in particular the fucose level of all of the antibodies of the composition being less than 60%, and preferably less than 50%, and in particular, the galactosylation level of all of the antibodies of the composition being at least 60%, for the use thereof in the context of the prevention or treatment of the early phases of inflammation. A composition including monoclonal antibodies directed against a circulating bacterial toxin, having an improved affinity for the fcγriiia receptor (cd16) with respect to antibodies directed against the bacterial toxin, produced in the cho cell line, for the use thereof in the context of the prevention or treatment of the early phases of a bacterial infection linked to the release of the toxin is also described..

06/30/16
20160184330 

Suppression of cytokine release and cytokine storm


The present invention includes methods and compositions for ameliorating symptoms or treating one or more adverse reactions triggered by infectious diseases or disease conditions that trigger a widespread release of cytokines in a subject comprising the steps of: identifying the subject in need of amelioration of symptoms or treatment of the infectious diseases or disease conditions that trigger a widespread release of cytokines; and administering one or more pharmaceutical compositions comprising a therapeutically effective amount of a curcumin extract, curcuminoids or synthetic curcumin (s-curcumin) and derivatives thereof, or empty liposomes, dissolved or dispersed in a suitable aqueous or non-aqueous medium sufficient to reduce the level of cytokines in the host.. .

06/30/16
20160184012 

Methods for monopolar renal neuromodulation


Methods and apparatus are provided for monopolar neuromodulation, e.g., via a pulsed electric field. Such monopolar neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers.

06/23/16
20160176941 

Cd40l collectin fusion proteins


The present invention refers to a fusion protein comprising a tnf-superfamily (tnfsf) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof.

06/23/16
20160176927 

Peptide for suppressing osteoclast differentiation and use thereof


The peptide of the present invention performs a function, which is the same as or similar to that of natural interleukin (il)-3, and has superior skin permeability due to the small size thereof. In addition, the peptide of the present invention suppresses the activation of nf-κb and nuclear transition by inhibiting the receptor activator of nuclear factor kappa-b ligand (rankl)-rank signaling pathway, and suppresses the expression of a rankl or an inflammatory cytokine-induced tartrate-resistant acid phosphatase (trap), cathepsin k, or tnf receptor type 1 or type 2, thereby inhibiting osteoclast differentiation depending on the treatment concentration.

06/23/16
20160175459 

Il-15 and il-15raplha sushi domain based modulokines


The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an immunomodulatory antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and a polypeptide comprising the amino acid sequence of the sushi domain of the il-15rα or derivatives thereof; and uses thereof.. .

06/23/16
20160175398 

Chimeric immunoreceptor useful in treating human cancers


The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of t lymphocytes, direct t cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific.

06/23/16
20160175397 

Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1


The present invention relates to the combination therapy of specific tumor-targeted il-2 variant immunocytokines with specific antibodies which bind human pd-l1.. .

06/16/16
20160169906 

Methods for identifying autoimmune arthritis and for screening for inhibitor of activation of autoimmune arthritogenic t cells


Provided are a method for identifying the presence or likelihood of autoimmune arthritis, the method comprising detecting (1) an anti-ribosomal protein l23a antibody or (2) ribosomal protein l23a-reactive cd4+ t cells in a sample derived from a subject; and a method for screening for a substance that inhibits the activation of autoimmune arthritogenic t cells, the method comprising the steps of bringing a test substance into contact with ribosomal protein l23a-reactive t cells, bringing the t cells into contact with ribosomal protein l23a or a fragment thereof, measuring the level of a proinflammatory cytokine secreted from the t cells, and analyzing the test substance-dependent change in the secretion level of the proinflammatory cytokine.. .
Kyoto University


06/09/16
20160159875 

Targeting of cytokine antagonists


The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling.
Centre Hospitalier Regional Universitaire De Montpellier


06/09/16
20160159874 

Targeted modified tnf family members


The present invention relates to a modified cytokine of the tnf superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the tnf superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells.
Centre Hospitalier Regional Universitaire De Montpellier


06/02/16
20160152730 

Targeted modified il-1 family members


The present disclosure relates to a modified interleukin-1 (il-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the il-1 family member cytokine is a mutant, more preferably it is a mutant il-1 with low affinity to the il-1 receptor, wherein said mutant il-1 is specifically delivered to target cells.
Centre Hospitalier Regional Universitaire De Montpellier


06/02/16
20160152705 

Use of a cd6 binding partner and method based thereon


The present disclosure relates to methods for treatment and prevention of disease conditions mediated by t-helper 17 (th17) and/or t-helper 1 (th1) t lymphocytes (t cells). In particular, the present disclosure relates to use of anti-cd6 antibody for treatment of disease conditions mediated by auto-reactive th17 and th1 t lymphocytes.
Center Of Molecular Immunology


06/02/16
20160151473 

Vaccines using high-dose cytokines


The present invention relates to the field of cancer immunotherapy. In particular, vaccines are administered in conjunction with high doses of cytokines to enhance an anti-tumor immune response..
Sunnybrook And Women's College Health Sciences Center


05/26/16
20160146831 

Antibody and cytokine biomarker profiling for determination of patient responsiveness


Compositions and methods are provided for prognostic classification of autoimmune disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of circulating blood levels of serum autoantibodies and/or cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness.
The Board Of Trustees Of The Leland Stanford Junior University


05/26/16
20160146806 

Receptors for b7-h4


Isolated cell surface receptors for b7-h4 have been identified based on function. B7-h4 receptor activation by b7-h4 on the dendritic cell, t follicular helper cell and germinal center b cell membrane stimulates inhibitory signaling in those leukocytes.
Amplimmune, Inc.


05/26/16
20160143940 

Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems


Psa is delivered to the host by outer membrane vesicles (omvs), secretion structures that target bacterial molecules to host cells. Purified omvs direct the in vitro differentiation of functional tregs with potent suppressive activity in a psa dependent manner.
California Institute Of Technology


05/19/16
20160136205 

Targeting type i nkt cells to control inflammation


Embodiments are directed to methods and compositions for modulating cytokine responses in subject infected by a pathogen.. .
The Board Of Regents Of The University Of Texas System


05/19/16
20160136204 

Production and therapeutic uses of th1-like regulatory t cells


A unique cd4+cd25+ regulatory t cell population develops from naive cd4+cd25− t cells during a th1 polarized immune response (called th1-tr cells). These th1-tr cells can be generated by contacting naïve t cells with mature cd8α+ dendritic cells (dcs) that have been exposed to a th1 polarizing adjuvant and, in some cases, an antigen of interest.
The Board Of Trustees Of The Leland Stanford Junior University


05/12/16
20160131663 

Biomarker for psychiatric and neurological disorders


The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free κ immunoglobulin chains and free λ immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders.
Resvo Inc.


05/12/16
20160130357 

Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same


Provided are isolated nucleic acid molecules encoding chimeric antigen receptors (cars) that bind to tumor antigens. Also provided are isolated polypeptides and cars encoded by the isolated nucleic acid molecules, vectors that include the isolated nucleic acid molecules, cells that include the isolated nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered t cells in a subject, expanding a population of genetically engineered t cells in a subject, modulating the amount of cytokine secreted by a t cell, reducing the amount of activation-induced calcium influx into a t cell, providing an anti-tumor immunity to a subject, treating a mammal having a muc1-associated disease or disorder, stimulating a t cell-mediated immune response to a target cell population or tissue in a subject, and imaging a muc1-associated tumor..
The University Of North Carolina At Charlotte


05/12/16
20160129110 

Immunoprotective primary mesenchymal stem cells and methods


Immunoprotective primary mesenchymal stems cells (ip-msc) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The ip-msc express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (scfv), fab or f(ab)2 antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., il-2, il-4, il-6, il-7, il-9, and il-12), an interferon (e.g., ifnα, ifnβ, or ifnω), and the like, which can enhance the effectiveness of the immunoreactive polypeptides..
The Administrators Of The Tulane Educational Fund


05/12/16
20160129109 

Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer


The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (at-car) system which provides t cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, αfitc-car-expressing t cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive fitc-labeled antibodies.
University Of Maryland, Baltimore


05/05/16
20160120970 

Compounds and methods for affecting cytokines


The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of tnf-a, lactoferrin, ifn-γ, il-i β, serum amyloid-a (saa), il-6 and/or β-defensin associated with infection or an immune response generally..
Zivo Biosciences, Inc.


04/28/16
20160116484 

Systems and methods for characterizing kidney diseases


The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine.
Renovar Incorporated


04/28/16
20160116469 

Immunologically active polypeptide


Disclosed are immunomodulatory polypeptides that behave as weak tlr2 and tlr4 agonists and as potent competitive antagonists of natural pathogenic ligands for human and murine tlr2 and tlr4, that identify a subset of neutrophils in human peripheral blood leukocytes, and that elicit an unusual induced cytokine profile. Also disclosed are compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including for treating sepsis or reducing the severity or likelihood of occurrence of sepsis, in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry.
Institute Of Arthritis Research, Llc


04/28/16
20160115227 

Administration of an anti-interleukin 12/23 antibody for treatment of autoimmune disease


The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of ustekinumab is administered to the subject.

04/28/16
20160114078 

Treatment of skeletal voids with implantable substrate hydrated with bone marrow concentrate


The invention is directed to a bone void filler comprising a scaffold or matrix. The scaffold or matrix may include a porous inorganic matrix component.
Spinesmith Partners, L.p.


04/28/16
20160114008 

Methods for accelerating the healing of connective tissue injuries and disorders


The invention is directed to methods for accelerating the healing of connective tissue injuries and disorders. In particular, the invention is directed to accelerating the healing of injuries and disorders of tendons and ligaments.
Stemnion, Inc.


04/21/16
20160108108 

Inflammatory disease diagnosis and methods of treatment using lipopolysaccharides-responsive beige-like anchor


Anti-cytokine therapy has revolutionized immunological disease treatment, but is not always effective and subject to treatment resistance as the cytokine cascade is highly redundant and multiple cytokines are involved in inflammation. Targeting a critical common regulator of inflammatory effectors is desirable.

04/21/16
20160108101 

Recombinant cancer therapeutic cytokine


Recombinant therapeutic cytokines (“therakines”) for the treatment of cancer are provided. The recombinant therakines include a truncated region of mda-7/tl-24 (“m4”) not normally found in nature that has anti-cancer activity and a secretory signal which causes secretion of the therakine from plasmid/virus transduced normal and cancer cells and interaction of the therakine to mda-7/il-24 receptors on adjacent, neighboring and distant cancer cells.

04/21/16
20160106887 

Medical device


The invention is directed to an improved medical device. In particular, the invention is directed to an improved medical device having a coating comprising novel cellular factor-containing solution compositions (referred to herein as cfs compositions), such cfs compositions including conditioned medium compositions obtained from culturing extraembryonic cytokine secreting cells (ecs cells), including amnion-derived cellular cytokine solution (referred to herein as accs) obtained from culturing amnion-derived multipotent progenitor (amp) cells, dispersed in a polymeric coating material..

04/21/16
20160106832 

Treatment of cancer with naltrexone


The present invention provides novel therapeutic applications of low dose naltrexone (ldn). Said applications have been determined in light of the discovery by the present inventors that naltrexone acts as an antagonist of toll-like receptor 9 (tlr9), an innate immune receptor which elicits the production of inflammatory cytokines when agonized.

04/14/16
20160101132 

Enhanced anabolic cytokine production and delivery system


Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins).

04/07/16
20160095954 

Fibrin microthreads


Compositions that include fibrin microthreads are provided. The compositions can include one or more therapeutic agents including cytokines and interleukins, extracellular matrix proteins and/or biologically active fragments thereof (e.g., rgd-containing peptides), hormones, vitamins, nucleic acids, chemotherapeutics, antibiotics, and cells.
Worcester Polytechnic Institute


04/07/16
20160095912 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


04/07/16
20160095911 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


04/07/16
20160095892 

Sour cherry topical biotherapeutic formulations, manufacture and treatment of human osteoarthritis symptoms


A biotherapeutic anti-inflammatory composition, its method of manufacture and method of treatment of various diseases, the composition having an efficacious amount of solid sour cherry seed extract and sour cherry seed oil sufficient to inhibit production of disease-associated inflammatory cytokines by cd3+ t lymphocytes in a vertebrate mammal.. .

03/31/16
20160091486 

Glatiramer acetate human monocytic cell line-based potency assay


The present invention relates to a method to determine the potency of a batch of glatiramer acetate comprising stimulating human monocytic cell line cells with an effective amount of interferon gamma (ifnγ), exposing said cells to said batch of glatiramer acetate, and determining the expression of the monocyte anti-inflammatory cytokine sil-1ra or the viability of said cells induced by glatiramer acetate.. .
Synthon B.v.


03/31/16
20160089426 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


03/31/16
20160089425 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


03/31/16
20160089424 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Ag


03/24/16
20160083442 

Inhibitors of the t cell-specific alternative p38 activation pathway and methods of use


In t lymphocytes, p38 mitogen activated protein kinase (mapk) can be activated through an alternative pathway that involves phosphorylation at tyrosine 323. Disclosed herein is the identification of a minimal region of the growth arrest and dna damage-inducible alpha (gadd45α) protein that is required for binding to and inhibition of tyrosine 323-phosphorylated p38 in t cells.
The U.s.a, As Represented By The Secretary Department Of Health And Human Services


03/24/16
20160082092 

Application of mrna for use as a therapeutic against tumour diseases


The present invention relates to a pharmaceutical composition comprising at least one mrna comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. Gm-csf, and a process for the preparation of the pharmaceutical composition.
Curevac Gmbh


03/24/16
20160082085 

Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer


The present invention relates to a combination of a parvovirus and a cytokine, preferably ifny, for use in treating pancreatic cancer, in particular a terminal stage of this disease.. .
Ruprecht-karls-universitaet Heidelberg


03/24/16
20160081958 

Use of methionine sulfoximine to treat diseases caused by an inflammatory cytokine response


Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (mso). The mso may be l-methionine s-sulfoximine (lsmso), l-methionine r-sulfoximine (lrmso), or diastereomeric mixture of lsmso and lrmso.

03/24/16
20160081913 

Composition for stimulating hair growth or preventing hair loss which includes extract neural stem cell and producing same


The present invention relates to a composition for stimulating hair growth or preventing hair loss, which contains a conditioned medium or extract of neural stem cells (nscs) isolated from the ventricular zone of the human brain, and to a preparation method thereof. The conditioned medium or extract of neural stem cells according to the present invention contains various growth factors and cytokines, and thus has an excellent effect on the stimulation of hair growth.
Korea University Research And Business Foundation


03/24/16
20160081329 

Modulating ischemic injury and preserving/storing tissue


The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs.
Stemnion, Inc.




Cytokine topics: Antibodies, Inflammation, Specificity, Immunotherapy, Major Histocompatibility Complex, Compatibility, Combination Therapy, Histocompatibility, Immune Response, Monoclonal Antibody, Stimulator, Therapeutics, Immunostimulator, Monoclonal, Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.844

4469

469495 - 0 - 101